We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Low-Dose CT Screening Drastically Improves Lung Cancer Long-Term Survival

By HospiMedica International staff writers
Posted on 08 Nov 2023

Lung cancer tops the list as the most deadly form of cancer. More...

The American Lung Association notes that only about 18.6% of those diagnosed with lung cancer survive beyond five years. Early detection is rare, with just 16% of cases discovered at an initial stage, and sadly, more than half of individuals with lung cancer pass away within a year of their diagnosis. While the treatment of late-stage cancers has improved with therapies that target cancer cells and bolster the immune system, detecting lung cancer early, particularly through low-dose CT scans before symptoms emerge, is critical for saving lives. A comprehensive international study spanning two decades has now shown that early detection of lung cancer through low-dose CT scanning significantly increases the survival rate to 81% over 20 years. And when lung cancer was caught at Stage I, the earliest stage, the survival rate jumped to an impressive 95%.

Since 1992, the research team at the Icahn School of Medicine at Mount Sinai (New York, NY, USA) has been examining the impact of low-dose CT scans in identifying lung cancer early. This work resulted in the International Early Lung Cancer Action Program (I-ELCAP), which has brought together more than 89,000 individuals from over 80 institutions worldwide. Going forward into 2024, the program aims to broaden its reach, collaborating with clinical and governmental bodies to initiate lung screening initiatives in underrepresented and economically challenged nations across two additional continents. Earlier findings in 2006 had revealed a 10-year survival rate of 80% when lung cancer was spotted through CT screening. For the latest study, the team looked at 20-year survival rates.

The new findings highlight that 81% of the 1,257 participants diagnosed with lung cancer through the I-ELCAP had Stage I cancer, characterized by a small tumor confined to the lung without spreading to lymph nodes. For these Stage I cancers, the study noted an 87% long-term survival rate. This emphasizes the life-saving potential of low-dose CT scans for the early detection of lung cancer. Notably, the study also took into account individuals who smoked minimally, such as those with less than 10 pack-years of smoking history, and even non-smokers who were exposed to secondhand smoke. The 20-year follow-up data from the study underscores that patients with early-stage lung cancer identified via CT scans have remarkably better survival prospects. Early treatment of these small tumors can lead to their long-term remission and cure.

"It is the first time that 20-year survival rates from annual screening have been reported," said the study's lead author, Claudia Henschke, Ph.D., M.D., professor of radiology and director of the Early Lung and Cardiac Action Program at the Icahn School of Medicine at Mount Sinai in New York. "This 20-year survival rate of 81% is the estimated cure rate of all participants with lung cancers diagnosed by annual screening. This is a huge benefit compared to waiting for a diagnosis that, in usual care, is symptom-prompted."

Related Links:
Icahn School of Medicine at Mount Sinai


Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Pediatric Mask
Respire SOFT
New
Breast Imaging Monitor
Barco Coronis Onelook MDMC-32133 32MP
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Artificial intelligence (AI) standalone performance and reader performance with versus without AI assistance. (A) Receiver operating characteristics (ROC) curve for AI standalone performance in the US dataset (AUC 0.899, 95% CI 0.858 to 0.939). (B) ROC curve for AI standalone performance in the Korean dataset (AUC 0.963, 95% CI 0.946 to 0.975). (C) Pooled reader ROC without (AUC 0.718) versus with (AUC 0.852) AI assistance in the Korean dataset; P<0.001. AUC, area under the receiver operating characteristics curve. (Leonard Sunwoo et al., Journal of NeuroInterventional Surgery (2026). DOI: 10.1136/jnis-2026-025339)

AI Improves Non-Contrast CT Interpretation for Time-Sensitive Stroke Assessment

Acute ischemic stroke occurs when a blood vessel in the brain becomes blocked, requiring rapid diagnosis to enable timely reperfusion therapy. Emergency departments often use computed tomography angiography... Read more

Surgical Techniques

view channel
Image: Researchers developed a handheld photothermal mid-infrared spectroscopic imaging (MIRSI) system that measures just 8 square inches. Probe light from a visible (red) diode laser and pump light from a modulated quantum cascade laser (QCL) are coupled into optical fibers and delivered to a flexible, handheld imager (blue dashed box). The beams are combined at a short-pass dichroic mirror and focused onto the sample using an off-axis parabolic mirror (OAP). (Image Credit:Rohith Reddy, University of Houston)

Handheld Infrared Imaging Device Supports Tumor Margin Assessment During Surgery

Accurately determining tumor margins during surgery remains challenging. Frozen-section pathology takes time and can miss residual disease, potentially leading to repeat surgery and delayed therapy.... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.